Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 3Phase 4 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 5Tumor-Agnostic 4Thoracic 4Lymphoid 3Genitourinary 2Gastrointestinal 2Breast 1

Conditions

Neuroblastoma 2Lymphoma, Large-Cell, Anaplastic 2Neoplasms 1Lymphoma 1

Interventions

Cyclophosphamide 211Rituximab 193fludarabine 134fludarabine phosphate 91Vincristine 78Cytarabine 66Etoposide 65Doxorubicin 61Dexamethasone 60Lenalidomide 59venetoclax 55ibrutinib 55Prednisone 54Bendamustine Hydrochloride 51obinutuzumab 48Filgrastim 46Bortezomib 46Specimen Handling 42pembrolizumab 39Gemcitabine 39Methotrexate 38Melphalan 38Biopsy 38Peripheral Blood Stem Cell Transplantation 32Magnetic Resonance Spectroscopy 32Azacitidine 31Vorinostat 29Nivolumab 29Calcium Dobesilate 29Clofarabine 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Crizotinib × Lymphoid × Clear all
NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Pfizer

Phase 1 Terminated
44 enrolled 22 charts 1 FDA
CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

NCT01606878 2024-01-05

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Children's Oncology Group

Phase 1 Completed
46 enrolled 24 charts
CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT00585195 2023-02-08

PROFILE 1001

Pfizer

Phase 1 Completed
596 enrolled 81 charts
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡